LAX.SH
NATCO PHARMA LTD.·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
882.4
+0.55%52W Range
Market Cap
₹15,804.65 Cr
Traded: ₹32.29 Cr (0.20%) 0.0x
Free Float: ₹4,260.93 Cr (0.76% of FF traded)
Volume · 60D trend
3.64 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +15.0% | +15.0% | +15.0% | -- | -21.0% | Stable |
| Profit | +25.0% | +28.0% | +26.0% | -- | -33.0% | Decelerating |
| Return | +4.0% | -2.0% | +3.0% | +3.0% | -- | Stable |
| ROE | +19.0% | +19.0% | +23.0% | -- | -- | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 735 | 739 | 647 | 1,363 | 1,329 | 1,221 | 475 | 1,371 | 1,363 | 1,068 | 759 | 1,031 | 1,140 | 898 | 492 | 432 |
| Expenses | 549 | 612 | 489 | 784 | 758 | 673 | 436 | 567 | 558 | 571 | 490 | 573 | 612 | 559 | 387 | 337 |
| Operating Profit | 186 | 128 | 159 | 579 | 571 | 548 | 39 | 804 | 805 | 497 | 268 | 458 | 528 | 339 | 106 | 95 |
| OPM % | 25.0% | 17.0% | 25.0% | 42.0% | 43.0% | 45.0% | 8.0% | 59.0% | 59.0% | 47.0% | 35.0% | 44.0% | 46.0% | 38.0% | 22.0% | 22.0% |
| Other Income | 59 | 78 | 58 | 100 | 62 | 66 | 176 | 64 | 48 | 42 | 37 | 29 | 20 | 29 | 21 | 20 |
| Interest | 13 | 11 | 10 | 13 | 3 | 10 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 3 | 4 | 4 |
| Depreciation | 47 | 50 | 46 | 52 | 58 | 98 | 47 | 46 | 44 | 56 | 44 | 44 | 44 | 41 | 42 | 42 |
| Profit Before Tax | 186 | 144 | 161 | 614 | 572 | 506 | 164 | 818 | 804 | 478 | 256 | 440 | 500 | 324 | 81 | 70 |
| Tax % | 34.0% | -62.0% | 13.0% | 16.0% | 16.0% | 20.0% | 19.0% | 17.0% | 17.0% | 19.0% | 17.0% | 16.0% | 16.0% | 15.0% | 23.0% | 19.0% |
| Net Profit | 206 | 269 | 151 | 518 | 480 | 406 | 132 | 676 | 668 | 386 | 213 | 369 | 420 | 276 | 62 | 57 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 11.5 | 15.0 | 8.5 | 28.9 | 26.8 | 22.7 | 7.4 | 37.8 | 37.3 | 21.6 | 11.9 | 20.6 | 23.5 | 15.1 | 3.4 | 3.1 |
| Sales Growth (YoY) | -44.7% | -39.5% | 36.2% | -0.6% | -2.5% | 14.3% | -37.4% | 33.0% | 19.6% | 18.9% | 54.3% | 138.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -0.5% | 14.2% | -52.5% | 2.6% | 8.8% | 157.1% | -65.3% | 0.6% | 27.6% | 40.7% | -26.4% | -9.6% | 26.9% | 82.5% | 13.9% | -- |
| OP Growth (YoY) | -67.4% | -76.6% | 307.7% | -28.0% | -29.1% | 10.3% | -85.4% | 75.5% | 52.5% | 46.6% | 152.8% | 382.1% | -- | -- | -- | -- |
| OP Growth (QoQ) | 45.3% | -19.5% | -72.5% | 1.4% | 4.2% | 1305.1% | -95.1% | -0.1% | 62.0% | 85.4% | -41.5% | -13.3% | 55.8% | 219.8% | 11.6% | -- |
| Profit Growth (YoY) | -- | -34.0% | 14.0% | -23.0% | -28.0% | 5.0% | -37.0% | 84.0% | 59.0% | 40.0% | 241.0% | 550.0% | 31.0% | 646.0% | -23.0% | -13.0% |
| EPS Growth (YoY) | -57.0% | -34.1% | 13.9% | -23.5% | -28.1% | 5.2% | -37.5% | 83.5% | 59.0% | 42.8% | 248.4% | 562.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -22.9% | 76.8% | -70.8% | 7.8% | 18.2% | 205.5% | -80.3% | 1.3% | 73.0% | 81.6% | -42.3% | -12.2% | 55.3% | 343.1% | 9.7% | -- |
| OP Margin | 25.3% | 17.3% | 24.6% | 42.5% | 43.0% | 44.9% | 8.2% | 58.6% | 59.1% | 46.5% | 35.3% | 44.4% | 46.3% | 37.8% | 21.5% | 22.0% |
| Net Margin | 28.0% | 36.4% | 23.3% | 38.0% | 36.1% | 33.3% | 27.8% | 49.3% | 49.0% | 36.1% | 28.1% | 35.8% | 36.8% | 30.7% | 12.6% | 13.2% |
| Material Cost % | 20.1% | 20.9% | 20.6% | 12.4% | 17.5% | 20.4% | 17.4% | 12.9% | 13.2% | 13.3% | 21.4% | 20.9% | 17.2% | 28.8% | 23.4% | 24.5% |
| Employee Cost % | 24.4% | 21.4% | 24.6% | 14.7% | 12.7% | 13.1% | 29.8% | 11.1% | 10.4% | 13.3% | 16.1% | 11.9% | 12.1% | 13.2% | 21.4% | 25.5% |
| P/S | 4.54 | 3.74 | 3.99 | 4.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 13.81 | 10.95 | 11.69 | 11.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.71 | 1.85 | 2.10 | 2.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit
Investor Meet
Investor Presentation
Q1FY2026-27 Transcript for the Earnings call held on 14th August, 2026
Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited
Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.
Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-27
Investor Presentation for the Q1FY27
Board of Directors at their Meeting held on today i.e. 14th August, 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each
Outcome of Board Meeting
The Company will host an Earnings Call with Investors / Analysts on Friday, the 14th August, 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ....
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation ....
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....
Press Release: NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)
Natco Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram holdings Proprietary Limited
Order passed by Assistant Commissioner (ST)(FAC), Tenali Circle, Tenali, Andhra Pradesh
Compliance Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018
Outcome of Board Meeting
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Superannuation of Mr. N. Malleswara Rao, Vice President - Operations, Pharma Division, Kothur w.e.f. closure of business hours on 30th June, 2026
Closure of Trading Window
Newspaper Publication of Annual Audited Financial Results for the Quarter and Year ended March 31, 2026
Audio Link of Concall held on May 29, 2026
FY26 Earnings Call Investor Presentation
Audited Financial Results for the quarter and year ended 31st March, 2026
Audited Financial Results for the quarter and year ended 31st March, 2026
Annual Secretarial Compliance Report for FY 2025-26
Q4FY26 Audited Financial Results Earnings Call
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve considering Audited Financial ....
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Compliance Certificates under Regulation 74(5) of SEBI (DP) Regulation, 2018
Trading Window closure for the quarter and year ending March 31, 2026
E-voting Results of Postal Ballot Results
Outcome of the Board Meeting for incorporation of subsidiary Company in Nigeria
Outcome of the Board Meeting held on 24th March, 2026
Outcome of Board Meeting
NATCO Pharma Limited launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price starting from MRP INR 1290/-
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/03/2026 ,inter alia, to consider and approve the Scheme of Arrangement (demerger)
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Satya Vani Nannapaneni
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjay Nannapaneni
Investor Meet
Natco announces launch of Pomalidomide Capsules (generci of Pomalyst) in the U.S. market
Clarification on the News Item
The Exchange has sought clarification from Natco Pharma Ltd on February 25, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Clarification on volume Movement of Shares
The Exchange has sought clarification from Natco Pharma Ltd on February 24, 2026, with reference to news appeared in https://www.livemint.com dated February 24, 2026 quoting "Eris Lifesciences ....
copy of News Paper Publication
Postal Ballot Notice seeking approval for reappointment of Executive Directors of the Company
Transcript of Q3 FY ''26 Post Results Earnings Conference Call
Annual Reports
14Credit Ratings
6Concalls
47Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jul 2025
31 Jul 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Jan 2025
31 Jan 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jul 2021
31 Jul 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jul 2020
31 Jul 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Sep 2019
30 Sept 2019Aug 2019
31 Aug 2019Jun 2019
30 Jun 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Nov 2017
30 Nov 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Feb 2017
28 Feb 2017Nov 2016
30 Nov 2016Sep 2016
30 Sept 2016Aug 2016
31 Aug 2016Jun 2016
30 Jun 2016Feb 2016
29 Feb 2016Held by ETFs
18 ETFs hold natcopharm · sorted by weight
Held by Mutual Funds
35 schemes hold natcopharm · sorted by weight